SCHEDULE: Vanguard Group Reports 0% Stake in Catalyst Pharma

The Vanguard Group has reported a 0% beneficial ownership in Catalyst Pharmaceuticals Inc. following an internal realignment.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 2 to Schedule 13G for Catalyst Pharmaceuticals Inc. Common Stock.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership of Catalyst Pharmaceuticals Inc. Common Stock.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately, and The Vanguard Group, Inc. no longer aggregates these holdings.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as largely neutral for Catalyst Pharmaceuticals Inc. as it primarily reflects an internal reporting realignment by The Vanguard Group rather than a divestment based on Catalyst's performance. However, the optics of a major institutional investor reporting 0% ownership could be perceived negatively by some.

Negatives

• The Vanguard Group, a prominent institutional investor, no longer reports beneficial ownership in Catalyst Pharmaceuticals Inc., which could be perceived as a reduction in institutional interest, even if due to an internal reporting change.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Catalyst Pharmaceuticals Inc.'s future outlook.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that institutional ownership changes, even due to internal restructurings, can sometimes influence market perception. While this filing primarily reflects an internal reporting change by Vanguard, a significant reduction to 0% beneficial ownership by a major fund group like Vanguard could be scrutinized by investors looking for broad institutional support for Catalyst Pharmaceuticals Inc. This is a common occurrence for large asset managers to re-organize their reporting structures.

Stakeholder Impact

• Shareholders of Catalyst Pharmaceuticals Inc. might perceive a decrease in institutional interest, potentially leading to minor short-term sentiment shifts, though the underlying reason is administrative.
• The Vanguard Group's internal realignment impacts its own reporting structure and how its various funds' holdings are aggregated and disclosed.

Key Dates

Recommendation

The filing indicates an administrative change in how The Vanguard Group reports its beneficial ownership, resulting in 0% reported ownership for Catalyst Pharmaceuticals Inc. This is not a performance-driven divestment but an internal realignment. Therefore, a seasoned investor would likely hold their position, as this filing does not provide new fundamental information to warrant a change in investment strategy for Catalyst Pharmaceuticals Inc.

Keywords

Catalyst Pharmaceuticals Inc, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, common stock, investment adviser, realignment